HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for ITeos Therapeutics, maintaining a price target of $46. This suggests confidence in the company's future performance.
September 16, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for ITeos Therapeutics, maintaining a price target of $46. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $46 price target by HC Wainwright & Co. indicates a positive outlook on ITeos Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100